Treatment of fever (Humma) with Unani medicine Habb-e-Karanjawa

Phase 3

Not yet recruiting

• Conditions: Fever, unspecified,

• Registration Number: CTRI/2021/09/037012
• Lead Sponsor: Central Council for Research in Unani Medicine CCRUM New Delhi

Brief Summary

This study is designed as a multicentric open trial in patients with **Humma (Fever).**After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria.  The patients will be assessed clinically at every 3rd day.  This includes subjective assessment of general well being and physical examination . The total duration of treatment will be one week. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy. 

Composition of *Habb**e-Karanjawa*

| | | | |

| --- | --- | --- | --- |

|**S. No.**

**Ingredients**

**Botanical / English Name**

**Quantity**

|

Maghz-e-Karanjawa

*Caesalpinia bonducella*

One piece

|

Tutiya-e-Sabz Biryan

Green Vitriol (Ferrous Sulphate)

125 mg

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-10
• Last Update Posted: 2021-09-29

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

• Participants of either sex in the age group 18 to 60 years 2.
• History of onset of fever within 24 hr 3.
• Participants with oral temperature ≥100 0F presenting with any of the following symptoms: Body ache Headache Joints pain Shivering Chills Sweating Palpitation Skin Flushing.

Exclusion Criteria

• Intake of any antipyretic drugs in the previous 8 hrs.
• Participant having oral temperature of ≥ 1040F 3.
• Known high risk clinical conditions such as pneumonia, sepsis, dengue haemorrhagic fever,meningitis, hepatitis B, etc.
• Immuno-compromised clinical conditions such as HIV/AIDS, cancer, etc.
• Known cases of other clinically significant co-morbid conditions (severe hepatic, renal, cardiovascular disorders, etc.) that in the opinion of the investigator could affect the efficacy and safety outcome of the study.
• Thrombocytopaenia defined as absolute platelet count below 50000/ cu.mm.
• Pregnant and Lactating females.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in signs and symptoms of Humma (Fever)	1 week

Secondary Outcome Measures

Name	Time	Method
Haematological and biochemical assessment for safety assessment	At baseline and after one week

Trial Locations

Locations (1)

National Research Institute of Unani Medicine for Skin Disorders, Hyderabad; 🇮🇳 Hyderabad, TELANGANA, India

National Research Institute of Unani Medicine for Skin Disorders, Hyderabad

🇮🇳Hyderabad, TELANGANA, India

Dr Mohammed Nawab

Principal investigator

8100992044

ccrumnawab@gmail.com